Abstract Both CD4 + Th17-cells and CD8 + cytotoxic T lymphocytes (CTLs) are involved in type 1 diabetes and experimental autoimmune encephalomyelitis (EAE). However, their relationship in pathogenesis of these autoimmune diseases is still elusive. We generated ovalbumin (OVA)-or myelin oligodendrocyte glycoprotein (MOG)-specific Th17 cells expressing RORγt and IL-17 by in vitro co-culturing OVA-pulsed and MOG 35-55 peptide-pulsed dendritic cells (DC OVA and DC MOG ) with CD4 + T cells derived from transgenic OTII and MOG-T cell receptor mice, respectively. We found that these Th17 cells when transferred into C57BL/6 mice stimulated OVA-and MOG-specific CTL responses, respectively. To assess the above question, we adoptively transferred OVA-specific Th17 cells into transgenic rat insulin promoter (RIP)-mOVA mice or RIP-mOV A mice treated with anti-CD8 antibody to deplete Th17-stimulated CD8 + T cells. We demonstrated that OVA-specific Th17-stimulated CTLs, but not Th17 cells themselves, induced diabetes in RIPmOVA. We also transferred MOG-specific Th17 cells into C57BL/6 mice and H-2K b−/− mice lacking of the ability to generate Th17-stimulated CTLs. We further found that MOG-specific Th17 cells, but not Th17-activated CTLs induced EAE in C57BL/6 mice. Taken together, our data indicate a distinct role of Th17 cells and Th17-stimulated CTLs in the pathogenesis of TID and EAE, which may have great impact on the overall understanding of Th17 cells in the pathogenesis of autoimmune diseases.
and represent an independent lineage of CD4 + Th cells [1, 2] . The discovery of CD4 + Th17 subset not only changes the classical Th1/Th2 paradigm of Th differentiation, but also markedly facilitates our understanding of immune responses under both physiological and pathological conditions [3, 4] . The differentiation and regulation of Th17 cells have been extensively studied. Transcriptional factors RORγt and STAT3 are critical and are required for the development of Th17 cells [5, 6] , and cytokine transforming growth factor (TGF)-β, IL-6, and IL-21 are critical for initiation and differentiation of Th17 cells [7] [8] [9] [10] .
Accumulated data suggest that Th17 cells play an important role in host defense against microbial infections and in the pathogenesis of autoimmune diseases such as type 1 diabetes (T1D) and experimental autoimmune encephalomyelitis (EAE) [11] . In T1D, the involvement of CD8 + T cells in pathogenesis has been recognized. T1D is caused by autoimmune destruction of insulin-producing islet β cells of the pancreas [12] . Antigen-specific CD8 + T cells have been found in the peripheral blood of T1D patients [13] . Studies in a nonobese diabetic (NOD) mouse model of T1D have indicated that CD8 + T cells inflict damage to islet β cells both at the early stage in diabetes development and at the final effector phase of the disease [14] [15] [16] . On the contrary, there is some preliminary evidence showing that Th17 cells may be considered as a contributing factor in the pathogenic process of T1D. For example, it has been found that IL-17 is expressed in the pancreas of T1D mouse model [17] , and the reduction of Th17 cells with the induction of IFN-γ inhibited IL-17 production and restored normoglycemia at the prediabetic stage [18] . However, the relative contribution of Th17 cells and CTLs in T1D has not been addressed.
EAE is a rodent model that has been valuable for the characterization of the immunopathogenic processes of human multiple sclerosis (MS). Attention has originally been focused on the role of CD4 + T cells in the induction of EAE because susceptibility to MS is associated with MHC class II genes [19] [20] [21] and the critical role of CD4 + Th17 cells in pathogenesis of EAE has, eventually, been demonstrated [22] [23] [24] [25] [26] . Recently, both CD4 + Th17 and CD8 + T cells have been identified in active lesions in brains of MS patients [27] . It has been shown that myelin oligodendrocyte glycoprotein (MOG)-specific CD8 + T cell responses are involved prior to and after the onset of EAE [28, 29] , and adoptive transfer of MOG-specific CD8 + T cells can also induce EAE [30] [31] [32] . However, (a) the potential relationship between the pathogenic CD4 + Th17 and CD8 + T cells and (b) the extent of their relative involvement in the pathogenesis of T1D and EAE are still not very clear.
Intercellular membrane transfer through trogocytosis plays an important role in immune modulation [33] . We have recently demonstrated that ovalbumin (OVA)-specific T cell receptor (TCR) transgenic OT II mouse CD4 + Th1 cells in vitro activated by OVA-specific dendritic cells (DC OVA ) acquired DC OVA 's peptide-MHC (pMHC) I and co-stimulatory molecules and became capable of directly stimulating antigen-specific CD8 + cytotoxic T lymphocyte (CTL) responses leading to antitumor immunity in wildtype C57BL/6 mice [34, 35] and diabetes in transgenic rat insulin promoter (RIP)-mOVA mice expressing islet β-cell antigen OVA [36, 37] . Based on the phenomenon of trogocytosis, we speculate that CD4 + Th17 cells may similarly acquire pMHC I by APC activation and become capable of stimulating CD8 + T cell responses in autoimmune diseases such as T1D and EAE.
In this study, we generated OVA-specific CD4 + Th17 cells and MOG-specific CD4 + MOG-TCR-Th17 cells by cultivating OVA-pulsed dendritic cells (DC OVA ) or MOG peptide-pulsed dendritic cells (DC MOG ) with CD4 + T cells derived from T cell receptor transgenic OTII mice or MOG-TCR transgenic mice, respectively. We also generated MOGspecific CD4 + Th17 by culturing MOG peptidepulsed splenocytes with CD4 + T cells purified from C57BL/6 mice with MOG immunization-induced EAE in presence of IL-6/IL-23/TGF-β. Through the utilization of this experimental model, we found that CD4 + Th17 cells acquired pMHC I in the process of activation by dendritic cells (DCs) and became capable of stimulating OVA or MOG-specific CD8 + CTL responses, when transferred into the mice. To assess the pathogenic behavior of CD4 + Th17-and Th17-induced CD8 + T cells in T1D and EAE, we transferred OVA-and MOG-specific CD4 + Th17 cells into RIP-mOVA and C57BL/6 mice, where both CD4 + Th17-and Th17-stimulated CD8 + CTL populations co-existed. We also used anti-CD8 antibody treatment in RIP-mOVA mice to deplete Th17-stimulated CD8 + T cells or employed H-2K b−/− mice lacking the endogenous CD8 + population to independently assess the effect of CD4 + Th17 cells or of Th17-stimulated CD8 + CTLs in pathogenesis of T1D and EAE. These experiments have clearly showed a distinct role of CD4 + Th17-and Th17-stimulated CD8 + CTLs in pathogenesis of autoimmune diseases demonstrating that T1D is directly mediated by CD8 + lymphocytes, whereas EAE appears to be induced by the CD4 + Th17 cells.
Materials and Methods
Reagents, Antibodies, Cell Lines, and Animals
The biotin-labeled anti-CD4 (GK1. These transgenic RIP-mOVA mice express OVA under the control of RIP. They are transgenic for truncated OVA gene that is expressed as a membrane bound molecule in pancreatic islets, kidney proximal tubules, and testis of male mice [38] . All mice were housed in the animal facility at the Saskatoon Cancer Center and treated according to Animal Care Committee guidelines of University of Saskatchewan.
Preparation of Dendritic Cell and OVA-Specific CD4 + Th1 and CD8 + Tc1 Cells
Bone marrow-derived DCs were generated in presence of GM-CSF (20 ng/ml) and IL-4 (20 ng/ml) as described previously [39] . DC derived from wild-type C57BL/6 mice were pulsed with OVA (0.3 mg/ml) overnight at 37°C, and termed as DC OVA . DC derived from MOG-TCR transgenic mice were pulsed with MOG peptide (20 μg/ml) for 2 h at 37°C, and termed as DC MOG . OV A-pulsed DC generated from H-2K b−/− was referred to as (K b−/− )DC OVA . The preparation of DC OVA -activated OVA-specific OT II CD4 + type 1 help T (Th1) and OT I CD8 + type 1 cytotoxic T (Tc1) cells was previously described [35, 40] .
OVA-and MOG-specific CD4 + Th17 Cell Preparation Spleens were removed from OT II, transgenic MOG-TCR, and EAE-induced mice, and were mechanically disrupted to obtain a single-cell suspension. The erythrocytes were lysed using 0.84% ammonium chloride. Naïve T cells were enriched by passing through nylon wool columns (C&A Scientific Inc, Mannose, VA). Naïve OVA-specific CD4 + T cells were then purified by negative selection using antimouse CD8 (Ly2) paramagnetic beads (DYNAL Inc, Lake Success, NY). To generate OVA-specific CD4 + Th17 cells, naïve CD4
+ T cells (2×10 5 cells/ml) from OT II mice were stimulated for 3 days with irradiated (4,000 rads) DC OVA (1×10 5 cells/ml) in the presence of IL-6 (10 ng/ml), IL-23 (10 ng/ml), TGF-β (5 ng/ml), and anti-IFN-γ antibody (20 μg/ml). These in vitro-activated CD4 + Th17 cells were separated by Ficoll-Paque (Sigma) density gradient centrifugation, further purified by positive selection using CD4-microbeads (Miltenyi Biotech, Auburn, CA). In vitro + Th17 cells were generated by incubation of irradiated (4,000 rad) wild-type C57BL6 mouse splenocytes with CD4 + T cells purified from spleens of MOG immunization-induced EAE mice with clinical score ≥2.5 at 1:1 ratio in presence of MOG peptide (20 μg/ml), IL-6 (10 ng/ml), IL-23 (10 ng/ml), and TGF-β (5 ng/ml). MOGspecific CD4 + MOG-TCR-Th17 cells were generated by costimulating naïve CD4 + T cells (2×10 5 cells/ml) from MOG-TCR transgenic mice with irradiated (4,000 rads) DC MOG (1×10 5 cells/ml) in the presence of IL-6 (10 ng/ml), IL-23 (10 ng/ml), TGF-β (5 ng/ml), and anti-IFN-γ antibody (20 μg/ml) for 3 days. Three days subsequent to incubation, MOG-specific CD4 + Th17 and CD4 + MOG-TCR-Th17 cells were purified by positive selection using CD4-microbeads.
Phenotypic Characterization of OVA-and MOG-specific CD4 + Th17 Cells
The above CD4 + Th17 cells were stained with a panel of Abs and analyzed for expression of various cell-surface molecules by flow cytometry. To measure intracellular expression of cytokines, CD4 + Th17 cells were processed using a commercial kit (Cytofix/CytoPerm Plus with GolgiPlug; BD-Biosciences, San Diego, CA) and stained with PE-conjugated anti-IFN-γ, IL-17, perforin, T-bet, and RORγt Abs. Culture supernatants of these OVA-specific and MOG-specific CD4 + Th17 cells re-stimulated with irradiated (4,000 rad) OVAII peptide-pulsed and MOG peptide-pulsed LB27 cells, respectively, were analyzed for cytokine expression using ELISA kits (Endogen, Cambridge, MA).
CD8
+ T Cell Proliferation Assays peptide immunization or Th17 cell injection.
Cytotoxicity Assays
In in vitro cytotoxicity assay, Th17-activated OTI CD8 + Tc1 cells were used as effector (E) cells, while 51 Cr-labeled EG7 and EL4 cells were used as target (T) cells in a chromium release assay. For testing the killing mechanisms, the effector cells were preincubated with CMA (1 μM) and emetin (5 μM) for 2 h before incubation with the target cells to prevent perforin and Fas/FasL interaction-mediated cytotoxicity. Specific killing was calculated as: 100× [(experimental cpm−spontaneous cpm)/(maximal cpm− spontaneous cpm) as previously described [34] . In in vivo cytotoxicity assay, C57BL/6 mouse splenocytes were incubated with either high (3.0 μM, CFSE high ) and low (0.6 μM, CFSE low ) concentrations of CFSE, and pulsed with OVAI or MOGI peptide and Mut1 peptide, respectively, and i.v. injected at 1:1 ratio into the OVA-specific or MOGspecific CD4 + Th17 cell-transferred and MOG peptideimmunized mice. Sixteen hours after target cell delivery, the spleens were removed, and residual CFSE high and CFSE low target cells remaining in recipient spleens were sorted and analyzed by flow cytometry.
RT-PCR
Total RNAwas extracted with Qiagen RNeasy purification kit (Qiagen, Mississauga, Ontario, Canada) as per manufacturer's protocol. Qiagen quantitative reverse transcription kit (Qiagen) was used to synthesize cDNA. Later, RORγt and GAPDH were analyzed by conventional PCR analysis. Following primer pairs were used for RT-PCR; RORγt: 5′ GCGGAGCAGACACACTTACA 3′, 5′ TTGGCAAACTC CACCACATA 3′ and GAPDH: 5′ CAGGTTGTCTCCTGC GACTT 3′, 5′ CTTGCTCAGTGTCCTTGCTG.3′. The protocol employed for amplification of mRNA comprised: 1 cycle of 94°C (5 min) and 25 cycles of 94°C (1 min), 52°C (1 min), and 72°C (1 min). All PCR reaction products were resolved using ethidium bromide stained 1% agarose gels. + and CD8 + T cells were similarly s.c. immunized with MOG peptide. Two days after immunization, these MOG-sensitized mice were i.p. injected with 400 ng pertussis toxin (PT; Sigma) [31] . EAE was also induced by i.v. adoptive transfer of MOGspecific CD4 + Th17 and CD4 + MOG-TCR-Th17 cells (5× 10 6 cells) into C57BL/6 or H-2K b−/− mice. Mice were examined daily for clinical signs. Mice were scored on scale of 0 to 5: 0, no clinical sign; 0.5, partially limp tail; 1, limp/flaccid tail; 2, moderate hind limb weakness; 2.5, one hind limb paralyzed; 3, both hind limbs paralyzed; 3.5, hind limbs paralyzed and weakness in forelimbs; 4, forelimbs paralyzed; and 5, moribund/death [31] . The analysis was performed on the raw data that included all clinical scores for each mouse at each time point in each group.
Histopathology
Pancreas was collected in 10% formalin from RIP-mOVA mice injected with CD4 + Th17 and PBS. Pancreatic tissue sections were stained with hematoxylin and eosin (H&E) and slides were assessed for inflammatory cell infiltration and tissue destruction in a blind fashion. EAE mice were extensively perfused with ice-cold PBS with 2 U/ml heparin (Sigma), and spinal cords were harvested and fixed in formalin. Sections (6 mm) were stained with Luxol fast blue (myelin stain) along with H&E counterstaining. Slides were assessed in a blind fashion for inflammation: 0, none; 1, a few inflammatory cells; 2, organization of perivascular infiltrates; and 3, increasing severity of perivascular cuffing with extension into adjacent tissue. For demyelination: 0, none; 1, rare foci; 2, a few areas of demyelination; and 3, large (confluent) areas of demyelination.
Statistical Analysis
Mouse survival and clinical score were analyzed using Log rank and Mann-Whitney U test [41, 42] , respectively, and all other experiments were tested for statistical differences using unpaired, two tailed, Student's t test. Differences were considered significant if p<0.05.
Results

CD4 + Th17 Cells Acquire pMHC I Complexes from DC OV A in the Course of Activation
To activate naïve OT II CD4 + T cells, we co-incubated them with irradiated DC OVA in the presence of the IL-23/IL-6/ TGF-β/anti-IFN-γ antibody cocktail. While naïve OT II CD4 + T cells did not express CD25, CD40L, CD69 and Ia b , the co-incubated CD4 + lymphocytes acquired the above molecules (Fig. 1a) , which clearly confirmed their activation status. The activated CD4
+ also expressed the cell-surface FasL, intranuclear RORγt [43] , and intracellular perforin, IL-17 ( Fig. 1a, b ), but not IL-4, indicating that they represented the CD4 + Th17 cells. To further confirm this, we performed RT-PCR analysis to show that these cells express transcription factor RORγt (Fig. 1c) , but not T-bet (data not shown). ELISA assays also revealed the CD4 + Th17 nature of the activated cell, since they proved to secrete the IL-2 (2.8 ng/ml), IL-6 (4.5 ng/ml), IL-17 (1.8 ng/ml), and TGF-β (0.2 ng/ml) cytokines. No CD11c + DC OVA contamination could be observed in these CD4 + Th17 cell populations (Fig. 1d) . We previously showed that CD4 + Th1 cells acquired DC's pMHC complexes in the course of DC activation [35] . In this study, we also showed that CD4 + Th17 cells resulting from DC OVA activation did display some DC's molecules such as pMHC I complexes (Fig. 1a) + T cell proliferation, we performed an OVA-specific tetramer staining assay in transgenic RIP-mOVA mice adoptively transferred with CD4 + Th17 cells [35] . As shown in Fig. 2c, CD4 + Th17 cells stimulated in vivo proliferation of OVA-specific CD8 + T cells accounting for 0.68% and 1.18% of total CD8 + T cell population in peripheral blood and pancreatic lymph nodes, respectively. To investigate the role of acquired pMHC I, we repeated the above assay using ( (Fig. 2d) . However, CD8 + T cell-induced killing activity to OVA-specific CFSE high target cells was lost in perforin −/− mice (Fig. 2d) , indicating that the in vivo CD4 + Th17-stimulated CD8 + T cell-induced killing activity to OVA-specific target cells is also via perforin-dependent pathway.
CD4
+ Th17 Cell-Induced Diabetes in Transgenic RIP-mOVA Mice is Mediated by Th17-Stimulated CD8 + CTLs
Interestingly, all (6/6) RIP-mOVA mice adoptively transferred with CD4 + Th17 cells carrying acquired pMHC I developed diabetes, while none (0/6) of the mice adoptively transferred with CD4 + (K b−/− )Th17 cells without acquired pMHC I complexes developed diabetes (Fig. 2e) . As expected, pancreatic islet tissues were destroyed and infiltrated with numerous lymphocytes in the diabetic mice (Fig. 2f) . To assess the importance of CD8 + T cells in pathogenesis of diabetes, we treated adoptively transferred mice with anti-CD8 Ab to deplete CD4 + Th17-stimulated OVA-specific CD8 + T cells. We found that this treatment completely prevented diabetes development in the experimental animals (0/6). The effect proved to be very specific, since similar treatment with control irrelevant antibody has not suppressed disease onset (Fig. 2e) To induce EAE, we s.c. administered MOG peptide to C57BL/6 mice, following previously described procedures [30] . All treated animals were found to develop chronicprogressive EAE with apparent clinical scores subsequent to MOG immunization (Fig. 3a) . To assess the MOGspecific CD8 + T cell responses, we performed MOGspecific PE-pentamer staining using tail blood from mice 2 weeks subsequent to the immunization with MOG peptide. We found that MOG peptide immunization stimulated in vivo proliferation of MOG-specific CD8 + T cells accounting for 0.56% of total CD8 + T cell population (Fig. 3b) , and these MOG-specific CD8 + T cells are cytotoxic effector cells since there was a substantial loss of the MOG-specific and CFSE high -labeled target cells (38%) in MOG -immunized mice (Fig. 3c) . Consistent with the above clinical finding, the histological examination of the spinal column revealed dramatic pathological changes in the immunized mice, with multiple inflammatory foci and extensive demyelination in the white matter of the spinal cord (Fig. 3d) . Mean inflammation and demyelination scores were 2.6 and 1.5, respectively (Fig. 3e ), which were significantly higher than in control animals (p<0.01). + T cells were subjected to flow cytometry, ELISA, and RT-PCR analysis. These CD4 + T cells proved to be, indeed, efficiently activated as they strongly expressed CD25 and CD69 on their membranes (Fig. 4a) . They also produced intracellular IL-17, but not IL-4, and expressed intranuclear RORγt, but not T-bet, indicating that they represent the CD4 + Th17 subset (Fig. 4a) . The RT-PCR analysis also revealed RORγt expression, thus further confirming the CD4 + Th17 nature of the obtained population (Fig. 4b) . As expected, they secreted the IL-2 (1.8 ng/ml), IL-6 (3.3 ng/ml), IL-17 (1.5 ng/ml), and TGF-β (0.1 ng/ml), confirming that they belong to CD4 + Th17 cells. To assess their potential stimulatory effect, we i.v. injected them into C57BL/6 mice and performed MOG-specific PE-pentamer staining assay. As shown in Fig. 4c , MOG-specific CD8 + T cells were detected in CD4 + MOG-TCR-Th17-immunized mice and accounted for 0.36% of the total CD8 + T cell population, indicating that MOG-specific CD4 + MOG-TCR-Th17 cells are capable of stimulating MOG-specific CD8 + T cell responses. To assess MOG-specific CD8 + T cell killing activity, we performed the in vivo cytotoxicity assay. A moderate (20%) loss of the MOG-specific, CFSE highlabeled target cells was observed in CD4 + MOG-TCRTh17 cell-transferred mice (Fig. 4d) , indicating that CD4 + MOG-TCR-Th17 immunization was likely to stimulate CD8 + T cell differentiation into effector CTLs with cytotoxic activity specific for MOG peptide-pulsed target cells. To examine their ability to induce EAE, we injected C57BL/6 mice with the in vitro-amplified CD4 + MOG-TCR-Th17 cells. All mice injected with MOG-specific CD4 + Th17 cells, but not with OVA-specific Th17 control, (Fig. 4e) . In addition, no significant difference in EAE initiation between C57BL/6 mice and H-2K b−/− mice lacking CD8 + T cells could be observed (Fig. 4e) , suggesting that CD4 + Th17 cells, but not Th17-stimulated CD8 + T cells, played a major role in EAE pathogenesis. Consistent with this clinical finding, histological examination of CNS tissues revealed pathological changes in C57BL/6 mice adoptively transferred with MOG-specific CD4 + MOG-TCR-Th17 cells (Fig. 4f) . In these adoptively transferred mice, multiple inflammatory foci and demyelination were observed in the white matter of the spinal cord, and mean inflammation and demyelination scores were 1.6 and 0.6, respectively, which was significantly higher than the control mice (p<0.01; Fig. 4g ).
CD4 + Th17 Cells Derived from EAE Mice also Play a Major Role in Pathogenesis of EAE
It has been demonstrated that in vivo-generated CD8 + T cells derived from MOG peptide-immunized mice can induce EAE after they are amplified in vitro by MOG peptide stimulation and then i.v. transferred into C57BL/6 mice [31] . To assess whether the in vivo-generated CD4 + Th17 cells derived from MOG peptide-immunized mice could also induce EAE, we amplified the MOGspecific CD4 + Th17 cells by culturing CD4 + T cells obtained from MOG -immunized mice with MOG peptide-pulsed splenocytes in the presence of IL-6, IL-23, and TGF-β. The amplified CD4 + T cells were purified using CD4-microbeads and phenotypically analyzed by flow cytometry, ELISA, and RT-PCR approaches. The purified CD4 + T cells proved to express CD25 and CD69 and produced IL-17 and RORγt, but not IL-4 or T-bet, confirming that they are active CD4 + Th17 cells (Fig. 5a,  b) . In agreement, they also secreted IL-2 (1.2 ng/ml), IL-6 (3.0 ng/ml), IL-17 (1.3 ng/ml), and TGF-β (0.1 ng/ml). To assess their potential stimulatory effect, we injected MOGspecific CD4 + Th17 cells into C57BL/6 mice and followed it by the MOG-specific PE-pentamer staining assay. As shown in Fig. 5c , MOG-specific CD8 + T cells accounting for 0.46% of the total CD8 + T cell population were detected in the injected mice, indicating that in vivo-generated MOG-specific CD4 + Th17 cells are also capable of stimulating MOG-specific CD8 + T cell responses. To assess MOG-specific CD8 + T cell killing activity, we performed the in vivo cytotoxicity assay. We observed a 22% reduction within the MOG-specific, CFSE high -labeled target cells in the MOG-CD4 + Th17 transferred mice (Fig. 5d) , showing again that MOG-CD4 + Th17 cells could stimulate CD8 + T cell differentiation into effector CTLs specifically targeting MOG peptide-pulsed target cells. To determine whether they are capable of inducing EAE, we injected C57BL/6 mice with the in vitro-amplified MOG-CD4 + Th17 cells originally obtained from MOG 35-55 -immunized mice. As shown in Fig. 5e , all C57BL/6 mice developed chronicprogressive EAE with apparent clinical scores occurring subsequent to adoptive transfer of MOG-specific CD4 + Th17 cells, but not OVA-specific Th17 control. In addition, there is no significant difference in EAE between C57BL/6 mice and CD8 + T cell-deficient H-2K b−/− mice, indicating that CD4 + Th17 cells, rather than Th17-stimulated CD8 + T cells, play a central role in EAE pathogenesis. Consistent with this clinical finding, histological examination of CNS tissues revealed pathological changes in C57BL/6 mice immunized with MOG-specific CD4 + Th17 cells (Fig. 5f ). In particular, multiple inflammatory foci and demyelination were observed in the white matter of the spinal cord of the immunized animals, with mean inflammation and demyelination scores of 1.1 and 0.6, respectively, which was significantly higher than the scores in control mice (p<0.01; Fig. 5g ).
Discussion
T1D is an organ-specific autoimmune disease characterized by predominantly T cell-mediated destruction of insulinproducing β-cells of the islets of Langerhans, culminating in the lifelong insulin dependence [44] . Before 1990, vast range of evidence favored a sole role of CD4 + T cells in T1D: (a) CD4 + T cells could be detected in abundance in islet cell infiltrates, (b) transfer of CD4 + T cells from NOD mice caused diabetes in disease free young mice [45] , and (c) the genetic region to which the defective genes mapped was the MHC II that interacts specifically with CD4 + T cells [46, 47] . The development of T1D has usually been ascribed to a CD4 + Th1 response with disease transfer in animal models being mediated by Th1 clones and lines [48, 49] . In addition, a potential involvement of Th17 cells in the course of T1D has recently been demonstrated in the mouse model [17] . However, over the time, new evidence has mounted implicating CD8 + T cells in T1D initiation and progression. The primacy of CD8 + T cells in autoimmunity, including diabetes, came into focus with a study of human monozygotic twins and NOD mice [50, 51] , that expressed low density of certain types of class I protein on the surface of APCs. Remarkably, similar studies in NOD mice also confirmed that the APCs of this spontaneously autoimmune animal model also had defects in MHC class I presentation [52] . It has been demonstrated that defects in loading of self antigens into class I polypeptides are associated with T1D pathogenesis [53, 54] , indicating that defects in class I assembly and loading could lead to T1D, as a result of a negative selection defect. It has also been shown that CD8 + T cells killed beta-cells expressing self-peptides in class I groove in murine models [55, 56] , suggesting that CD8 + T cells exert a strong role in the etiology of T1D.
To assess (a) the potential relationship between the pathogenic CD4 + Th17 and CD8 + T cells in T1D and (b) to determine the extent of their effect on pathogenesis of T1D, we generated RORγt-and IL-17-expressing OVAspecific CD4 + Th17 cells by co-culturing OVA-specific TCR transgenic OTII CD4 + T cells with OVA-pulsed DC OV A in presence of IL-6, IL-23, TGF-β, and anti-IFN-γ antibody. We found that (a) OVA-specific Th17 cells stimulated OVA-specific CTL responses via IL-2 and acquired pMHC I signaling when transferred into RIP- + CTLs in T1D, we transferred these Th17 cells into RIP-mOVA mice or RIP-mOVA mice with anti-CD8 Ab treatment to deplete Th17-stimulated CD8 + T cells. We showed that Th17-stimulated CD8 + CTLs, but not Th17 cells themselves were required for T1D induction in RIPmOVA mice (Fig. 6 ). Our findings are consistent with some previous reports showing that (a) transfer of islet-specific Th17 cells failed in diabetes induction, though it caused an extensive insulitis [57] , and (b) treatment with neutralizing IL-17-specific Abs did not prevent T1D in NOD/SCID mice, which were derived from transfer of highly purified Th17 cells from BDC2.5 transgenic mice [49] . Furthermore, autoreactive CD8 + T cells have been shown to play an important role in the pathogenesis of T1D [47, 58] . CD8 + CTLs kill target cells through two distinct cytolytic pathways, the perforin-dependent granule exocytosis and the Fas/FasL interaction pathways [59] . The perforin in the presence of calcium has the ability to insert into lipid bilayer membrane, polymerize, and form structural and functional pores that can lead to cell lysis, whereas the binding of FasL on CTLs to Fas initiates the death pathway of apoptosis in the Fas- + T cells were able to kill OVAexpressing target cells both in vitro and in vivo via perforin-dependent pathway [60] , indicating that CD4 + Th17 induces diabetes in RIP-mOVA mice, may be through OVA-expressing pancreatic beta-cells killing by CD4 + Th17-stimulated CD8 + CTLs via perforin-dependent pathway. In addition to T1D, we used EAE in our work as a model of human multiple sclerosis induced by autoreactive CD4 + Th cells that mediate tissue inflammation and demyelination in the central nervous system. EAE can be induced through adjuvant and pertussis toxin-based immunization of C57BL/6 mice with a peptide, representing a fragment of an external myelin component, the encephalitogenic MOG peptide. Following the immunization, myelin sheaths of oligodendrocytes are attacked [61] . Although the predominant evidence has shown the critical role of CD4 + Th17 cells in EAE pathogenesis [22] [23] [24] [25] [26] , a potential involvement of CD8 + T cells in EAE has also been recognized [28] + T cells are likely to play a critical role in MOG immunization-induced EAE in C57BL/6 mice. The apparent discrepancy between our findings and the previous report [62] may potentially result from genetic differences between different strains (DBA/1 and C57BL/6) of mice used in these two studies. DBA/1 mice are very sensitive to MOG immunization leading to EAE induction even in the absence of PT treatment, whereas C57BL/6 mice only develop MOG immunization-induced EAE, when mice are boosted with pertussis toxin, which greatly enhances CD4 + T cell responses [62] .
To further dissect (a) the potential relationship between the pathogenic CD4 + Th17 and CD8 + T cells in EAE and (b) to establish the extent of their influence on EAE pathogenesis, we generated two types of RORγt-and IL-17-expressing MOG-specific CD4 + Th17 cells by cultivation of (a) naïve CD4 + T cells derived from MOG-specific TCR transgenic mice and (b) primed MOG-specific CD4 + T cells derived from EAE mice. We found that both MOGspecific CD4 + Th17 cells were capable of stimulating MOG-specific CD8 + CTL responses when transferred into C57BL/6 mice. To assess EAE induction by these MOGspecific CD4 + Th17 cells or MOG-specific Th17-stimulated (Fig. 6) . The failure of in vivo CD4 + Th17-stimulated CD8 + CTLs to trigger EAE may be due to their efficiency being lower than the efficiency of in vitro expanded MOGspecific CD8 + T cells that were successful in EAE induction, when adoptively transferred into experimental mice [30] [31] [32] . Nevertheless, our observations indicate that CD4 + Th17 cells, but not in vivo Th17-stimulated CD8 + CTLs are likely to induce EAE under physiological conditions. Our data are also consistent with some recent reports showing that (a) IL-17A significantly contributes to the induction of EAE in immunized mice [63] and (b) adoptive transfer of MOG-specific Th17 cells induce EAE in C57BL/6 mice leading to the induction of EAE in wildtype C57BL/6 mice [22] . Increasing evidence suggests that Th17 cells mediate inflammatory responses through selective migration, accumulative retention at specific sites and secretion of inflammatory cytokines, such as IL-17 [64] inducing tissue inflammation, eventually leading to demyelination in the central nervous system [65] [66] [67] . EAE has long been considered the prototypic IFN-γ-secreting Th1-mediated autoimmune disease [68, 69] . Until some findings suggested a primary role for IL-17-secreting Th17 cells in this model [70, 71] . It has been shown that Th1 cells facilitate the entry of Th17 cells to the central nervous system during EAE [72] . Th1 and Th17 cells are shown to have different regulatory roles in inflammation of the brain and spinal cord [26] and EAE with different pathological phenotypes [73] . IFN-β was effective in reducing EAE symptoms induced by Th1 cells, but exacerbated disease induced by Th17 cells [74] . Therefore, this paradigm shift has sparked a rapid and remarkable change in emphasis in the search for disease-modifying drugs away from the Th1 pathway toward the Th17 pathway [75] .
Conclusions
Taken together, our study shows that CD4 + Th17 cells acquired pMHC I in the process of activation by DCs and became capable of stimulating OVA or MOG-specific CD8 + CTL responses, when transferred into the mice. Our data also elucidate a distinct role of CD4 + Th17 and Th17-stimulated CD8 + T cells in autoimmune diseases, that T1D being directly mediated by Th17-stimulated CD8 + cells, whereas EAE is likely to be triggered by CD4 + Th17 cells.
Therefore, this work may have great impact on the overall understanding of CD4 + Th17 cells in the pathogenesis of autoimmune diseases.
